Please login to the form below

pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib, an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,

Latest news

Baxalta and CTI complete filing for Jakafi rival in US

Baxalta and CTI complete filing for Jakafi rival in US. Myelofibrosis candidate pacritinib aiming for accelerated approval. ... Baxalta's former parent company Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m.
Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial. Myelofibrosis candidate pacritinib moves closer to market. ... Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal.
Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Baxter licenses cancer drug from CTI in $172m deal

Baxter licenses cancer drug from CTI in $172m deal. Pacritinib is being investigated to treat blood disorder myelofibrosis. ... he added, noting that additional data on pacritinib will be presented at the American Society of Haematology (ASH) conference
Sanofi pulls development of blood cancer drug

Therapeutics/Baxter's pacritinib.

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
Deal Watch table for November 2013

232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Pharma deals during November 2013

Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Associate Scientific Director: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Medical Writer - Creative and Scientific Projects: DOE

Account Manager: Negotiable

Systematic Review Lead- London: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Manager- 4 days per week or full-time: Salary TBC

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Account Director or Senior Account Director: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Subscribe to our email news alerts

PMHub

Add my company

Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...